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Abstract
Objective: To investigate the response of radiotherapy and
related clinicopathologic characterictics on cervical cancer
patients.
Methods: This was a retrospective study. Subjects were patients
diagnosed with cervical cancer stage IIA-IIIB who had undergone
radiation therapy based on standard protocol in our hospital, during
the period of January 2014 to December 2015. The clinical factors of
those patients, such as age, Body Mass Index, blood pressure, hemo-
globin level, blood leucocyte count, serum albumin, largest tumor
diameter, the International Federation of Gynecology and Obstetrics
(FIGO) staging, as well as pathologic characteristic, i.e histopatho-
logy and grading were recorded. During radiation protocol until 3
months post radiation, we also noted any side effects of gastro-
intestinal tract, genitourinary tract, and hematologic. Evaluation of
radiotherapy response was based on Response Evaluation Criteria
in Solid Tumors (RECIST).
Results: A total of 123 subjects were enrolled in this study. 84
cases or 68.29% was complete response, 30 cases or 24.39% was
partial response, 6 cases or 4.88% was stabile response, and 3
cases or 2.44% was progressive. Based on gastrointestinal side
effect, there was no side effect or grade 0 on 99 cases (80.49%),
grade 1 on 20 cases (16.26%), grade 2 on 4 cases (3.25%), grade
3 on 0 case (0%). Based on side effect of genitourinary, there was
no side effect or grade 0 on 105 cases (85.37%), grade 1 on 17
cases (13.82%), grade 2 on 1 case (0.81%), grade 3 on 0 case
(0%). Based on hematologic side effects, there was no side effect
on 108 cases (87.80%), grade 1 on 15 cases (12.20%), grade 2 on
0 case (0%), grade 3 on 0 case (0%). Largest tumor diameter was
statistically significant, with p=0.036 (RR 2.64 (1.07-6.56))
Conclusion: The majority of definitive-curative radiotherapy
response on cervical cancer stage IIA-IIIB was complete (68.29%).
Acute side effects involving the gastrointestinal, genitourinary,
and hematologic system were commonly can be tolerable during
and 3 months post radiation therapy. Clinicopathologic charac-
teristics significantly associated with the complete response of
radiotherapy was the largest tumor diameter.
[Indones J Obstet Gynecol 2017; 5-4: 230-235]
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Abstrak
Tujuan: Respon terapi radiasi dan karakteristik klinis serta pa-
tologi yang berhubungan pada pasien kanker serviks di RSCM.
Metode: Penelitian kohort ini dilakukan dengan menggunakan data
sekunder terhadap 123 pasien kanker serviks stadium IIA-IIIB yangmenjalani radiasi kuratif definitif sesuai protokol standard bulan
Januari 2014-Desember 2015 di RSUPN Dr. Cipto Mangunkusumo.
Dilakukan pencatatan karakteristik klinis dan patologis sebelumradiasi. Dicatat juga efek samping akut gastrointestinal, traktus
genitourinaria, dan hematologis selama menjalani protokol radiasisampai 3 bulan pascaradiasi. Data respon tiga bulan pascaradiasi
lengkap berdasarkan klinis dan pemeriksaan ultrasonografi trans-
rektal/transvaginal dicatat dan diklasifikasikan sesuai ResponseEvaluation Criteria in Solid Tumors (RECIST).
Hasil: Dari 123 kasus, 84 kasus (68,29%) diperoleh respon komplit,30 kasus (24,39%) respon parsial, 6 kasus (4,88%) respon stabil,
dan 3 kasus (2,44%) respon progresif. Berdasarkan efek sampingakut gastrointestinal, tidak didapatkan efek samping (derajat 0)
pada 99 kasus (80,49%), derajat 1 pada 20 kasus (16,26%), derajat
2 pada 4 kasus (3,25%), derajat 3 pada 0 kasus (0%). Berdasarkanefek samping akut genitourinaria, tidak didapatkan efek samping
(derajat 0) pada 105 kasus (85,37%), derajat 1 pada 17 kasus
(13,82%), derajat 2 pada 1 kasus (0,81%), dan derajat 3 pada 0kasus (0%). Berdasarkan efek samping akut hematologis, tidak
didapatkan efek samping (derajat 0) pada 108 kasus (87,80%),derajat 1 pada 15 kasus (12,20%), derajat 2 pada 0 kasus (0%), dan
derajat 3 pada 0 kasus (0%). Didapatkan hubungan bermakna
antara diameter tumor (p=0,036;RR 2,64; IK95 1,07-6,56) denganrespon radiasi komplit.
Kesimpulan: Gambaran respon radiasi kuratif definitif pada kankerserviks stadium IIA-IIIB di RSCM adalah 68,29% respon komplit. Efek
samping akut gastrointestinal, genitourinaria, dan hematologis padaumumnya tidak terjadi selama dan sampai 3 bulan pascaradiasi.
Sebagian besar efek samping akut yang terjadi berderajat rendah.
Terdapat hubungan bermakna antara diameter tumor terbesardengan respon komplit radiasi. Tidak terdapat hubungan bermakna
antara usia, Indeks Masa Tubuh, kadar hemoglobin, jumlah leukosit
darah, kadar albumin serum, stadium FIGO, jenis histopatologis, danderajat diferensiasi dengan respon terapi radiasi.
[Maj Obstet Ginekol Indones 2017; 5-4: 230-235]
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INTRODUCTION
According to the World Health Organization
(WHO), cervical cancer cases was the second
number of all women cancer and the seventh
number of all cancer around the world in 2010.1
In Indonesia, cervical cancer is the second number
of woman of age 15-44 years old. At Dr. Cipto
Mangungkusumo hospital, cervical cancer number
was 3112 cases found in 2007, which account for
75% of gynecologic cancer.2 These magnitude of
the incidence in Indonesia will add more health,
economic, and social burden in this country,
particularly for those women.
Another problem is the majority of them
admitted on advanced stage, with relatively low
survival rate. On advanced stage-IIb and higher,
radiation can be used interchangeably with
chemoradiation depend on patient condition. On
their research, Iskandar, et al revealed that there
was no diferrence in radiotherapy response among
cervical cancer patients at Dr. Cipto Mangun-
kusumo hospital who underwent radiation only
compare to chemoradiation.3 On the other side,
few studies done previously in same hospital
showed that it was difficult to a cervical cancer
patient complete her chemoradiation course of
treatment compare to radiotherapy.4 Therefore,
radiation therapy could be a main modality for
most of these patients. However, local tumor
control of radiotherapy is still not satisfied yet,
ranging from 20 to 50%. Failure to achieve local
tumor control would increase the morbidity and
the risk of developing distant metastatis. However,
if succesful, the survival rate could be increased as
many as 50%.5
Factors influencing the radiotherapy response
had been questioned and studied previously in
numerous centers. If such factors were clearly
identified and modified, it will gain our under-
standing in increasing radiotherapy response
and hence survival. An acute side effect during the
course could potentially making the patient
not to continue the treatment. Therefore, we
conducted a research to find out response rate of
radiotherapy, incidence of acute side effect, and
relation of routine and simple clinicopathologic
characteristic-i.e age, Body Mass Index (BMI),
blood pressure, blood hemoglobine level, blood
leucocyte count, serum albumin level, tumor size,
International Federation of Gynecology and
Obstetrics (FIGO) staging, histopathology and
grading-of patients in our hospital.
METHODS
This retrospective study used secondary data from
cervical cancer patients, who came to Dr. Cipto
Mangunkusumo hospital, department of radio-
therapy, during January 2014 to December 2015.
The data of the subject was included for further
analysis if the subject had been already diagnosed
with cervical cancer based on histopathology
examination, planned to have radiotherapy only
based on standard protocol, i.e external curative
dose of 46-50 Gy (25 times) using gamma 60 Co 1,2
megavolt and LINAC 4-10 Mega Volt continued to
brachytherapy using after loading method HDR
microselectron unit of 129I, dose 700cGy, three
times on A-point. Subjects suffering other primary
tumor as well as incomplete data were excluded.
The clinical factors of those patients prior to
radiation, such as age, Body Mass Index, blood
pressure, hemoglobin level, blood leucocyte count,
serum albumin, largest tumor diameter FIGO
staging and pathologic characteristic, i.e histo-
pathology and grading were recorded. During
radiation protocol until 3 months post radiation,
we also noted any side effects of gastrointestinal
tract, genitourinary tract, and hematologic.
Evaluation of radiotherapy response was based on
Response Evaluation Criteria in Solid Tumors
(RECIST). The collected data was further analysed
using Stata 13.
RESULTS
We had 123 cases for further analysis. The baseline
characteristic is shown in table 1. Among 123
cases, 84 cases or 68.29% was complete response,
30 cases or 24.39% was partial response, 6 cases
or 4.88% was stabile response, and 3 cases or
2.44% was progressive. Based on gastrointestinal
side effect, there was no side effect or grade 0 on
99 cases (80.49%), grade 1 on 20 cases (16.26%),
grade 2 on 4 cases (3.25%), grade 3 on 0 case (0%)
Based on side effect of genitourinary, there was no
side effect or grade 0 on 105 cases (85.37%), grade
1 on 17 cases (13.82%), grade 2 on 1 case (0.81%),
grade 3 on 0 case (0%). Based on hematologic side
effects, there was no side effect on 108 cases
(87.80%), grade 1 on 15 cases (12.20%), grade 2
on 0 case (0%), grade 3 on 0 case (0%).
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On bivariate analysis, p of each factors were age
(p=0.266; RR 0.87 (0.67-1.12)), Body Mass Index
(p=0.397), blood pressure classification (p=0.658;
RR 0.98 (0.76-1.27)), largest tumor diameter
(p=0.034; RR 1.30 (1.03-1.63)), hemoglobin level
(p=0.193; RR 0.98 (0.76-1.27)), blood leucocyte
count (p=0.969; RR 1.00 (0.78-1.29)), FIGO staging
(II vs III) (p=0.526; RR 1.08 (0.85-1.38)), histo-
pathology result (squamous cell carcinoma vs
nonsquamous cell carcinoma) (p=0.159; RR 1.18
(0.90-1.55)), and grading (p=0.469) (Table 2). On
multivariate analysis, tumor diameter was statis-
tically significant, with p=0.036 (RR 2.64 (1.07-
6.56)) (Table 3).
Table 1. Characteristics of Cervical Cancer Patients Underwent Radiation treatment only during January 2014 -
December 2015
Characteristics n (%) Mean SD Median (min­max)
Clinical Characteristics Age (years): 509 51 (26-74)
26-49 51 (41.46)
50-74 72 (58.54)
Body Mass Index (BMI) (kg/m2): 23.984.77 23.7 (14.3-46.6)
< 18.5 10 (8.13)
18.5 - 22.9 46 (37.40)
 23 67 (54.47)
Blood pressure (mmHg): 130.1719.50 / 79.6811.43 129 (90-189) / 82 (54-114)
Hypertension 43 (34.96)
No Hypertension 80 (65.04)
Blood hemoglobin level (g/dl) 11.481.45 11.3 (7.3-15.8)
< 10 12 (9.76)
 10 111 (90.24)
Blood leucocyte count (cell/mm3) 95894082 8480 (2960-19410)
 10.000 76 (61.79)
> 10.000 47 (38.21)
Serum albumin level (g/dl) : 3.990.73 4.2 (1.27-4.89)
< 3.5 9 (19.15)
 3.5 38 (80.85)
Largest tumor diameter (mm) 45.7918.78 40 (15-102)
< 40 45 (36.59)
 40 78 (63.41)
FIGO Staging N/A N/A
Stage IIA 4 (3.25)
Stage IIB 42 (34.15%)
Stage IIIA 7 (5.69)
Stage IIIB 70 (56.91)
PATHOLOGY CHARACTERISTICS
Histopathology type N/A N/A
Squamous cell carcinoma 89 (72.36)
Adenosquamous carcinoma 9 (7.32)
Adenocarcinoma 24 (19.51)
Neuroendocrine 1 (0.81)
Differentiation (grading) N/A N/A
Good 44 (35.77)
Moderate 58 (47.15)
Poor 21 (17.07)
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DISCUSSION
The majority of the subjects had complete
response, i.e 84 cases or 68.29%. This result
showed that our radiotherapy response is rela-
tively good, even though it is lower than previous
study-i.e 81.6% - on 38 patients in 2009 reported
by radiotherapy division of Dr. Cipto Mangun-
kusumo Hospital.6 The difference could be linked
to sample size and length of observation time.
However, study by Amin, et al in Dr. Soetomo
Hospital, Surabaya found similar result, i.e 70.4%
and no complete response 29.6%.7 Whether this
rate could be generalize as successful rate of radio-
therapy response of cervical cancer patients in
Indonesia should be further elaborated and
analized, considering that the protocol and subject
characteristics are still vary among centers.
Table 2. Bivariate Analysis
Characteristic
Complete
Response
No Complete
Response
p RR CI 95%
n % n %
Age (years) 26-49 32 38.10 19 48.71 0.266 0.87 0.67-1.12
50-7 52 61.90 20 51.29 Reff
Blood pressure Hypertension 29 34.52 14 35.90 0.882 0.98 0.76-1.27
Non Hypertension 55 65.48 25 64.10 Reff
Blood hemoglobin level < 10 6 7.14 6 15.38 0.193* 0.71 0.40-1.27
 10 78 92.86 33 84.62 Reff
Body Mass Index (BMI) Overweight 48 55.81 19 51.35 0.397 1.06 0.83-1.34
Non overweight 38 44.19 18 48.65 Reff
Blood Leucocyte Count (cells/l)  10.000 52 61.90 24 61.54 0.969 1.00 0.78-1.29
> 10.000 32 38.10 15 38.46 Reff
FIGO stage Stage II 33 39.29 13 33.33 0.526 1.08 0.85-1.38
Stage III 51 60.71 26 66.67 Reff
Largest tumor diameter (mm) < 40 36 42.86 9 23.08 0.034 1.30 1.03-1.63
 40 48 57.14 30 76.92 Reff
Histopathology type Squamous Cell
Carcinoma
65 75.58 24 64.86 0.159 1.18 0.90-1.55
Non Squamous Cell
Carcinoma
21 24.42 13 35.14 Reff
Differentiation Good 33 39.29 11 28.21 0.469 N/A N/A
Moderate 38 45.24 20 51.28
Poor 13 15.48 8 20.51
Serum Albumin Level < 3.5 5 14.71 4 30.77 0.198* 0.73 0.44-1.20
 3.5 29 85.29 9 69.23 Reff
*Fisher’s exact test
Table 3. Multivariate Analysis
Variable Coef. OR SE p
IK95%
Min Max
Hemoglobin -0.756 0.47 0.30 0.230 0.14 1.61
Tumor diameter 0.973 2.64 1.23 0.036 1.07 6.56
Histopathology type -0.549 1.73 0.76 0.213 0.73 4.11
  Constant -0.997
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This study also revealed that most of our subject
had low grade acute side effect, most experience
no side effect. All patient could complete the course
of treatment regardless this side effect. It further
stated that compare to chemoradiation with the
same effectivity, the side effect of radiation is much
tolerable.
Age has been shown as a clinical prognostic
factor for local control and survival in some
studies. Elantholi, et al revealed that age > 50 yo
was linked with higher no residual tumor.8 In our
study, more younger patient was found, but we still
can not prove its direct relationship with lower
complete response. Clinically, age group 26-50 yo
tend to decrease response 0.87 times compare to
age group > 50 yo. But statistically, age is not
significant determinant for complete response.
Simple nutritional status measured by BMI
showed that most of our subjects was overweight
to obese. This finding against the perception that
cancer patients on advanced stage was always
malnourished. Furthermore, the higher BMI on
advanced staged patients will add more risk of
mortality due to non cancer related factors.9 This
study showed that there is no significant relation
between BMI and complete response. Albumin
level as another way for measurement showed that
most of our subjects was not in hypoalbuminemic
state. Clinically said, albumin level < 3.5 g/dl tend
to decrease response 0.73 times, but remain
statistically unsignificant.
Previous studies showed that cancer lesion
diameter > 4 cm will be hard for being treated
compare to smaller size due to high association
with early onset distant metastasis.10 Aditionally,
larger tumor size often linked with radioresistant
cells due to high rate of mutation.11 Eiffel et al
studied 1526 patients underwent radiation only
found that control rate was 97% on tumor
diameter < 5 cm and 84% on tumor diameter 5-7
cm.12 Our finding showed that tumor size < 40 mm
was linked with better complete response (2.64
times) compare to tumor size  40 mm with
statistically significant result on both bivariate and
multivariate analysis.
More than half of subjects in our study was in
the stage IIIB. It showed that there was still many
patients came in late stage which was potentially
making the treatment become difficult. This
condition was different to India, as in Chufal et al’s
study showed that most of their patients was in
stage IIB.12 Regardless the fewer earlier stage in
our subject, we still had 4 cases of stage IIA who
underwent radiation therapy eventhough it was
not our standard procedure to include them in
radiation treatment. Due to patient preference to
refuse surgery, 3 patients asked for radiation
treatment. One patient had undergone laparotomy
but found inoperable and further continued to
radiotherapy. On bivariate analysis, we did not
find significant association of FIGO stage with
radiotherapy response.
Squamous cell carcinoma remains the most
common type as in our study, followed by adeno-
carcinoma. Garcia-Arias, et all in their study also
have similar finding. Recently there was increasing
incidence of adenocarcinoma but decreasing
incidence of squamous cell carcinoma. It could be
linked to better diagnostic classification used,
obesity, and more younger age at diagnosis.13
Reagen and Wentz stated that adenocarcinoma
was less sensitive to radiation that lead to poor
survival of such type. Meanwhile Fletcher, et al also
believed that poor survival of such type was
linked to miometrial invasion, thus it could spare
the radiation in most of treatment.14 However, in
our study, the response of radiotherapy of
squamous cell carcinoma group was comparable to
non squamous cell carcinoma.
Cervical cancer prognosis is also linked to
differentiation or grading. In our study, more
subjects was good and moderate differentiation,
similar with findings by Chufal, et al.12 On the
other side, the difference in grading will not result
in diferrence in radiotherapy response.
CONCLUSION
Most of definitive-curative radiotherapy responses
on cervical cancer stage IIA-IIIB were complete
(68.29%). Partial response was 24.49%, stable
response was 4.88%, and progressive was 2.44%.
The Acute side effects involving the gastro-
intestinal, genitourinary, and hematologic system
could be tolerated during and 3 months post
radiation therapy. The clinical characteristic that
significantly related to complete response of radio-
therapy was largest tumor diameter.
REFERENCES
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S,
Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence
Indones J
234  Winarto et al Obstet Gynecol
and Mortality Worldwide: IARC Cancer Base No. 11
[Internet]. Lyon, France: International Agency for Research
on Cancer; 2013. Available from: http://globocan.iarc.fr,
accessed on 11/ July/2016.
2. Azis MF. Masalah Kanker Serviks. Cermin Dunia Kedokteran
2001; 133: 5-7.
3. Iskandar, Andrijono, Supriana. Uji Klinik Kemoradiasi
dibanding radiasi terhadap respon infeksi HPV dan respon
klinik pada karsinoma sel skuamosa uteri. Maj Obstet
Ginekol Indones 2008; 32(4): 212-22.
4. Nuranna L, Gunawan R, Supriana N, Sutrisna B. Efek Tok-
sisitas dan Respon Terapi Radiasi dibanding Kemoradiasi
pada Kanker Serviks Stadium Lanjut Lokoregional di
RSUPN Dr. Cipto Mangunkusumo. Program Pendidikan
Konsultan Onkologi Ginekologi FKUI-RSCM: 2011.
5. Jacobs AJ, Faris C, Perez C, Kao M, Galakatos A, Camel M.
Short-Term Persistence of Carcinoma of The Uterine Cervix
After Radiation, An Indicator of Long Term Prognosis.
Cancer 1986; 57: 944-50.
6. Supriana N. Uterine Cervix Cancer Patient FIGO IIB - IVA,
January 2009 - December 2009, Radiotherapy Department,
Dr. Cipto Mangunkusumo Hospital. 2009.
7. Amin Y, Mulawardhana P, Erawati D. Demografi, Respon
terapi dan Survival Rate Pasien Kanker Serviks Stadium III-
IVA yang mendapat Kemoterapi Dilanjutkan Radioterapi.
Maj Obstet Ginekol, 2015; 23(3): 97-105.
8. Elantholi, Sushmita Ghoshal, Vinay Kumar, Rakesh Kapoor.
Prognostic value of response to external radiation in stage
IIIB cancer cervix in predicting clinical outcomes: A retro-
spective analysis of 556 patients from India. Radiotherapy
Oncol, 2006; 79: 142-6.
9. Kizer NT, Thaker PH, Gao F, Zighelboim I, Powell MA, Rader
JS, Mutch DG, Grigsby PW. The Effects of Body Mass Index
on Complications and Survival Outcomes in Patients With
Cervical Carcinoma Undergoing Curative Chemoradiation
Therapy. Cancer 2011; 117: 948-56.
10. Yaes RJ. Tumor heterogeneity, tumor size and radio resis-
tance. Int J Radiat Oncol Biol Phys. 1989; 17: 993-1005.
11. Wang, Wang, Yang, Chai, Shi, Lkiu. Patient age, tumor
appearance and tumor size are risk factors for early
recurrence of Cervical Cancer. Mol Clin Oncol, 2015;
3: 363-6.
12. Chufal KS, Chufal, Madhup Rastogi, Srivastava M, Pant MC,
Bhat MLB, Srivastava K. Concurrent chemoradiotherapy for
locally advanced cervical cancer using Gemitabine: non-
randomized comparison of three sequential protocols.
Cancer Therapy 2007; 5: 43-54.
13. Garcia-Arias, Candelaria, Cetina, et al. The prognostic
significance of leukocytosis in cervical cancer. Int J Gynecol
Cancer 2007; 17: 465-70.
14. Fletcher GH. Am. J. Roentgenol. Rad. Ther. Nucl. Med. 1971;
111: 225.
Vol 5, No 4
October 2017 Radiotherapy Response of Cervical Cancer Patients  235
